+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06726421

Phase III Trial Comparing Systemic Therapy With or Without Stereotactic Body Radiotherapy in Patients With Oligometastatic Kidney Cancer

Led by Sun Yat-sen University · Updated on 2026-01-15

252

Participants Needed

9

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of stereotactic body radiation therapy SBRT combined with standard systemic therapy for people with oligometastatic renal cell carcinoma, a form of kidney cancer with limited spread. This phase III randomized controlled trial compares whether adding SBRT to targeted agents and immunotherapy can prolong survival and affect quality of life and treatment side effects, compared to systemic therapy alone. The study also explores cancer progression, survival rates, and patient-reported outcomes. Participants are randomly assigned to one of two groups one group receives standard systemic therapy alone, and the other group receives SBRT targeted to all metastatic sites in addition to the same systemic therapy. The SBRT is delivered with a dose schedule determined by the treating radiation oncologist, aiming for a biologically effective dose of at least 115, and treatment to all lesions is ideally completed within 3 to 6 months after enrollment. Systemic therapies include drugs like axitinib, lenvatinib, cabozantinib, sunitinib, and pazopanib, with or without immune checkpoint inhibitors. Throughout the trial, participants undergo imaging tests such as CT, PETCT, and MRI scans to monitor cancer progression. Researchers measure progression-free survival from enrollment up to five years, along with overall survival, cancer-specific survival, local tumor control, and treatment-related toxicities over up to two years. Quality of life is assessed using questionnaires at regular intervals. The entire study duration can last up to five years to gather comprehensive data on treatment effects and safety.

CONDITIONS

Brief Title

Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)

Research Team

L

Liru He, PhD

F

Fangjian Zhou, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here